Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Pembrolizumab Monotherapy in Patients with Refractory Esophageal Cancer Conveys Modest Efficacy
Read More
JAVELIN Gastric 100 Clinical Trial Results Demonstrate No Advantage for Avelumab vs Continued Chemotherapy
Read More
EMERGE Clinical Trial Phase 2A Domatinostat Dose Escalation
Read More
PLATFORM Trial Analysis for Durvalumab Demonstrates Patient Subset Gained Radiological Response
Read More
CheckMate-577: Nivolumab Adjuvant Therapy in Patients with Resected Esophageal or GEJ Cancer Is Associated with Significant Disease-Free Survival
Read More
Retrospective Study of Nivolumab Monotherapy Treatment Lines
Read More
LEAP-005 Clinical Trial Yields Promising Efficacy and Safety Data for Patients with Gastric Cancer
Read More
CheckMate-648: Nivolumab with Ipilimumab or Chemotherapy Improves OS in Patients with Advanced Esophageal Squamous-Cell Carcinoma
Read More
DisTinGuish Part A Trial of DKN-01 plus Tislelizumab and CAPOX Results Indicate Early Activity in Patients with Advanced DKK1-High Gastroesophageal Adenocarcinoma
Read More
CheckMate-649: Survival Outcome Improved in Patients with Advanced Gastric/Esophageal Cancer Treated with Nivolumab Combined with Chemotherapy
Read More
1
2
3
Page 3 of 3
Results 21 - 30 of 30
